BCL2 and cancer: These markers not only cover the classical senescence markers of CNS, but also include the molecules reflecting the hallmarks of cancer senescence including cell cycle arrest (CDKN1A, CDKN2A, CDKN2B, CDKN2D, MTOR, PCNA, SATB1, and TP53), DNA damage response (MACROH2A1), anti-apoptotic pathway activation (BCL2), increased lysosomal content (GLB1, LGALS3, and LGALS3BP), and nuclear change (LMNB1) (Table S1).